Scott Foster

Scott Foster

Company: Genentech Inc

Job title: Principal Scientist

Seminars:

Expert Panel Discussion: To Degrade or Not to Degrade – Rationale Behind Selecting Inhibitory or Degradation Modality 3:00 pm

Highlighting the advantages of using a degrader vs. catalytic site inhibitors and optimizing PKPD Optimizing the linker, linage and E3 ligand for maximal binding and optimizing residency time Discussing the issues of translating degradation efficiency to the clinic with different kinase inhibitorsRead more

day: Day One

Degradation Is Not Always Superior to Enzymatic Inhibition: Lessons Learned from EGFR Heterobifunctional Degraders 2:00 pm

Targeted degradation of EGFR failed to suppress resistance common to EGFR targeted therapies Degradation resulted in decreased efficacy relative to non-degrader controls Comparing degrader vs non-degrader controls highlighted an unexpected role for ER stress contributing to the efficacy of canonical EGFR targeted therapiesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.